Explainer: What the recent trials have shown

In December 2023, surgeons at Massachusetts General Hospital transplanted a kidney from a genetically modified pig into a 57‑year‑old man with end‑stage renal disease. The organ functioned for 271 days – the longest period a xenograft has survived in a human – before the patient received a deceased‑donor kidney.1 The pig was edited with CRISPR to delete three genes that trigger human immune rejection (GGTA1, CMAH, B4GALNT2) and to add a human complement‑regulatory protein (hCD46). This combination reduces hyperacute rejection and limits inflammation.

The evidence comes from a single‑patient case series, but it is supported by parallel work at the University of Maryland and other centres that have reported similar short‑term survival of pig hearts and livers in primates. The Harvard Medical School team published the patient’s progress, noting that the xenograft maintained normal creatinine levels and allowed the recipient to stop dialysis.2

BBC reported that the kidney’s performance was “stable enough to keep the patient alive until a human organ became available”, while The Economist highlighted that the approach could “buy time for patients on long waiting lists”. Researchers emphasise that the trial was carefully controlled: patients received intensive immunosuppression, and the organ was monitored for viral transmission, a known theoretical risk of xenotransplantation.

“The pig kidney acted as a functional bridge, demonstrating that genetically edited xenografts can sustain human physiology long enough for a conventional transplant,” the Harvard team wrote.

While promising, the data are still limited. One patient cannot establish safety or efficacy for the broader population, and long‑term outcomes beyond a year remain unknown. Ongoing Phase I/II trials aim to enrol up to ten patients across the United States, which will provide a clearer picture of rejection rates, infection risk, and quality of life.

Domesticated farm pig lying in the mud head covered in dry earth under the sun in Don Det Laos
Domesticated farm pig lying in the mud head covered in dry earth under the sun in Don Det Laos (Image: Wikimedia Commons)

Guide: Why this matters and what patients can expect

  • Reduced waiting time. For patients in regions with long transplant queues, a pig kidney could serve as a temporary bridge, avoiding prolonged dialysis and its complications.
  • Eligibility criteria. Current trials enrol adults with end‑stage renal disease who are medically stable, have no suitable human donor, and can tolerate strong immunosuppression.
  • Procedure and monitoring. The surgery mirrors a standard kidney transplant, but post‑operative care includes weekly blood tests for kidney function, viral screening (especially for porcine endogenous retroviruses), and close immunologic monitoring.
  • Potential risks. Besides conventional transplant risks—bleeding, infection, rejection—there is a theoretical risk of zoonotic virus transmission, though no such event has been observed in the human trials to date.
  • Transition to a human organ. In the reported case, the pig kidney functioned for nine months, after which a human kidney became available. Future protocols aim to use the xenograft as a bridge rather than a permanent solution.

Patients considering participation should discuss trial specifics with their transplant team, understand the experimental nature of the procedure, and weigh the benefits of reduced dialysis against the uncertainties of a novel therapy.

Myth‑buster: Common misconceptions about xenotransplantation

Myth 1: Pig organs will instantly trigger a fatal immune reaction. This belief stems from early xenograft attempts before genetic engineering. Modern CRISPR edits remove the major carbohydrate antigens that cause hyperacute rejection, and early human data show that grafts can survive for months with standard immunosuppression.

Myth 2: Xenotransplantation will spread animal diseases to people. The concern originates from the presence of porcine endogenous retroviruses (PERVs) in pig DNA. However, the pigs used in the current trials are bred in biosecure facilities, and extensive viral screening has found no PERV transmission in the patients reported by STAT and NIH‑funded studies. Ongoing surveillance remains a core component of the trials.

Removing bioprinted construct
Removing bioprinted construct (Image: Wikimedia Commons)

Myth 3: Pig organs are a permanent replacement for human kidneys. At present, xenografts are viewed as a bridge. The longest‑surviving pig kidney lasted 271 days, after which the patient received a human donor organ. Researchers do not yet claim that pig kidneys can replace the need for human donors indefinitely.

Myth 4: Ethical concerns make xenotransplantation impossible. Ethical debates focus on animal welfare and consent. The pigs are raised specifically for research under strict veterinary oversight, and many ethicists argue that the potential to save human lives justifies the practice when performed responsibly.

In short, while xenotransplantation is still experimental, the evidence to date shows that genetically edited pig kidneys can function in humans long enough to bridge the gap to a conventional transplant, offering a realistic new option for patients facing long waiting lists.

Anyone with specific health questions about transplant options should discuss them with a qualified healthcare professional.